Speakers
 *denotes AACR member
Targeting redox active iron in cancer therapy
Bryan Allen, MD, PhD*
Dr. Allen is an MD, PhD (in Biochemistry) physician scientist early stage new investigator who transitioned from a Holman Pathway research residency program to an academic tenure track assistant professor position in Radiation Oncology at the University of Iowa in 2013. Dr. Allen is also a cancer survivor who has dedicated the next phase of his career to translational oncology research for the purpose of using a basic science understanding of metabolic oxidative stress in cancer biology to design novel and rapidly implementable new combined modality cancer therapies. During the first half of his research residency, Dr. Allen published a seminal first author paper in Clinical Cancer Research using ketogenic diets to enhance metabolic oxidative stress for the purpose of enhancing radio-chemotherapy for lung cancer (PMID: 23743570). In collaboration with his mentors at Iowa (Dr. Douglas Spitz and Dr. John Buatti), this has resulted in an NIH funded R21 Phase 1 clinical trial (CA161182) to extend these pre-clinical observations into NSCLC patients as well as similar trials in pancreas cancer and head and neck cancer patients. In the second half of his research residency and the first four years of his faculty position, Dr. Allen (in collaboration with Drs. Cullen, Buettner, Spitz, Buatti, and Hohl) studied the basic science mechanisms by which pharmacological ascorbate can selectively act as a pro-oxidant in brain and lung cancer vs. normal cells for the purpose of developing novel combined modality chemo-radio-therapies resulting in a publication in Cancer Cell. Finally, Dr. Allen has participated in phase 1 and 2 clinical trials to use superoxide dismutase mimics to protect against mucositis in head and neck cancer patients receiving radio-chemotherapy.
University of Iowa  
   
Targeting NAD metabolism in cancer therapy
David Boothman, PhD*
Dr. Boothman grew up in Detroit, Michigan, and earned his B.S. at the University of Michigan-Ann Arbor.  He did his graduate work in microbiology and immunology at the University of Miami Medical School, where he received his PhD under the mentorship of Dr. Sheldon Greer. His research focused on the biochemistry and pharmacology of anticancer drugs, specifically 5-fluoro-deoxycytidine derivatives.
He did postdoctoral research at the Dana-Farber Cancer Institute of Harvard Medical School with Dr. Arthur B. Pardee. There, he investigated changes in several aspects of cancer cells before and after cell stress: cell cycle checkpoint regulation, molecular biology, and gene expression. His studies on β-lapachone as a radiosensitizer and DNA repair inhibitor began at this time. Dr. Boothman also discovered and cloned the first proteins and transcripts induced by ionizing radiation (IR).
In 1990, Dr. Boothman became Assistant Professor at the University of Michigan-Ann Arbor and continued his investigations of x-ray-inducible proteins (Boothman et al., Cancer Research, 1988), and x-ray-inducible transcripts leading to proteins (Boothman et al., PNAS, 2000). He discovered xip8 (clusterin) and its induction by super-low levels of IR exposure. Dr. Boothman then joined the faculty in the Department of Human Oncology at the University of Wisconsin-Madison, where he rose to Associate Professor with tenure and became the Vice Chairman of Radiation Oncology, and Division Head of Molecular Radiation Oncology.
In 1998, Dr. Boothman accepted an Endowed Professorship at Case Western Reserve University and became heavily involved in the Cancer Center. In 2000, he became the Associate Director for Basic Science and headed the research effort in the Cancer Center’s Wolstein Research Building.
In 2005, Dr. Boothman and his close colleague Dr. Jinming Gao moved to  UT Southwestern Medical Center to start the Cell Stress and Cancer Nanomedicine Program.
UT Southwestern Medical Center  
   
H2O2 as a radio-chemo-sensitizer
Joseph Cullen, MD*
Joseph J. Cullen, M.D., is a Professor of Surgery at the University of Iowa Carver College of Medicine with a secondary appointment in the department of Radiation Oncology. He is Chief of Surgical Services at the Iowa City VA Medical Center. He is a member of the NIH Radiation Therapeutics and Biology study section. His research interests funded by the NIH are directed towards investigating the role of pharmacological ascorbate for the treatment of pancreatic cancer. 
University of Iowa  
   
Positron Emission Tomography- FDG-PET and beyond
John Floberg, MD, PhD
John Floberg is a 3rd year radiation oncology resident in the Department of Radiation Oncology at Washington University in St. Louis. He completed the medical scientist training program at the University of Wisconsin, earning his Ph.D. in medical physics. His graduate work focused on novel image processing methods and positron emission tomography (PET) imaging under the guidance of Chuck Mistretta, PhD, Jamey Weichert, PhD, Jim Holden, PhD, and many others.
John started his clinical residency in radiation oncology in 2015, and is participating in the Holman Research Pathway under the mentorship of Julie Schwarz, MD, PhD. His goal is to become a physician scientist at the completion of his training. In Dr. Schwarz’s lab, he is expanding his training to better understand the relationship between cancer biology and imaging. His research focus is on developing approaches to imaging redox potential and oxidative stress in cervical cancer and multi-modality clinical imaging markers. He is fortunate to have been supported by ASTRO and RSNA resident seed grants while undertaking this work.
Washington University School of Medicine  
   
Sexual dimorphism in tumor metabolic phenotypes
Joseph Ippolito, MD, PhD
Dr. Ippolito graduated from Cornell University with a B.S. in Biochemistry (summa cum laude) and joined the Medical Scientist Training Program (MSTP) at Washington University in Saint Louis. There, he received an M.D. and Ph.D. in molecular biophysics under the mentorship of Dr. Jeffrey Gordon where he developed new methods to identify metabolic signatures associated with poor prognosis in castrate-resistant neuroendocrine prostate cancers. He then entered the Diagnostic Radiology residency program at the Mallinckrodt Institute of Radiology in Saint Louis under the mentorship of David Piwnica-Worms M.D., Ph.D. followed by a clinical fellowship in body magnetic resonance imaging.  Although he continues his laboratory research program combining metabolomics and PET imaging to investigate metabolic crosstalk in neuroendocrine prostate cancer, he has started a new NIH-funded research program to characterize the developmental origins of sex differences in brain tumor glucose metabolism through novel mouse models, metabolomics, and PET imaging. 
Washington University School of Medicine  
   
MR and EPR redox imaging
Murali Krishna Cherukuri, PhD
Dr. Krishna obtained his Ph.D. in physics from the Indian Institute of Technology, Madras, India, in 1984 and joined the NCI the same year. He became an independent investigator in 1993. His research interests include studies of free radical processes in causing oxidative injury and antioxidant defense. More recently, he has been involved in developing functional imaging tools to study tumor physiology."
National Cancer Institute Center
for Cancer Research
 
   
Hyperpolarized 13C MR imaging in cancer
John Kurhanewicz, PhD
 
John Kurhanewicz, PhD is a Professor in Residence in the Departments of Radiology and Biomedical Imaging, Urology and Pharmaceutical Chemistry at University of California, San Francisco, and a member of the California Institute for Quantitative Biology and UCSF Cancer Center, and faculty in the UCSF-UCB Bioengineering Graduate Group. He is the Director of the UCSF Body Research Interest Group, the Pre-Clinical Imaging Core, and the Prostate Cancer Imaging Program at UCSF. Dr. Kurhanewicz received his BS in Chemistry from the University of South Florida/New College in 1982, and obtained his PhD in Physical Organic Chemistry from the University of South Florida, Tampa in 1987, followed by a postdoctoral fellowship in MRI/MRS from the University of California, San Francisco in 1990. Dr. Kurhanewicz has published over 250 peer-reviewed manuscripts and 19 book chapters, and has been cited 19,491 times (citation indices: h-index of 75, i10-index - 196). He is a member of 7 scientific societies, serves on numerous scientific review panels for the National Institute of Health, Department of Defense and American Cancer Society and reviews for over 30 different journals.

Dr. Kurhanewicz and his colleagues have developed a large prostate cancer imaging program at UCSF, involving the application of advanced magnetic resonance imaging techniques (metabolic, diffusion and perfusion weighted MRI) to provide a more accurate assessment of the extent and aggressiveness of prostate cancer in individual patients. This multiparametric 1H MRI prostate cancer staging exam is currently being used to help over 2,000 men diagnosed with prostate cancer a year at UCSF to decide on their best therapeutic course. He is also internationally recognized for my work in metabolic biomarker discovery and their clinical translation and have developed two important pre-clinical platforms to facilitate these biomarker discovery efforts. He pioneered quantitative high-resolution proton magic angle spinning (1H HR-MAS) spectroscopy that allows for the identification of metabolic biomarkers from snap frozen biopsies and surgical tissue and NMR/PET compatible 3D cell and tissue culture bioreactors that allow the metabolic study of living patient derived cells and tissues. Finally, Dr. Kurhanewicz is involved in the development and clinical translation of an extraordinary new metabolic imaging technique utilizing hyperpolarized 13C labeled metabolic substrates that has the potential to revolutionize the way MR imaging is used in the risk assessment of prostate cancer patients. He led the first clinical trial of this technology at UCSF and is involved in multiple ongoing clinical trials investigating its clinical utility.
University of California, San Francisco  
   
Using SOD mimics in cancer therapy
Rebecca Oberley-Deegan, PhD
Associate Professor, Department of Biochemistry and Molecular Biology at the University of Nebraska Medical Center
Education/Training:
B.A. Grinnell College, Grinnell, Iowa
Ph.D. University of Iowa, Iowa City, Iowa
Postdoctoral training at National Jewish Health, Denver, CO
Research:
Rebecca Oberley-Deegan’s laboratory has previously shown that a catalytically active antioxidant can protect normal prostate tissues during radiation but not prostate tumor tissues. The focus of her research is determining the mechanisms by which antioxidants can protect normal tissues from radiation while simultaneously making the tumor vulnerable to radiation damage. Dr. Oberley-Deegan’s is focusing specifically on the role of free radical signaling to transform fibroblasts and inflammatory cells in normal tissues, which results in damage to these tissues. In the context of prostate cancer, her group is focusing on inhibiting the signaling events controlled by radiation-induced free radicals involved in tumor survival and metastasis.


University of Nebraska Medical Center  
   
Glycolytic serine synthesis and nucleotide production
Michael Pacold, MD, PhD
 
Michael Pacold is an Assistant Professor of Radiation Oncology at New York University Medical Center. He earned a PhD in Molecular Biology from the University of Cambridge and an MD from Harvard Medical School, followed by residency in the Harvard Radiation Oncology Program and a postdoctoral fellowship at the Whitehead Institute, MIT and the Dana-Farber Cancer Institute, where he was also an Instructor in Radiation Oncology. He is interested in the chemical biology of metabolism.
NYU Langone Medical Center  
   
Beyond Warburg- using untargeted metabolomics to study alternate metabolic pathways in cancer
Gary Patti, PhD
The Patti laboratory develops mass spectrometry and NMR-based metabolomic technologies to study metabolic regulation in mammalian systems at the molecular level. Dr. Patti holds the Michael and Tana Powell Professorship in the Department of Chemistry at Washington University in St. Louis.
Washington University St. Louis  
   
Plenary: Targeting cancer cell metabolism using tumor immunology and cellular responses to oxygen deprivation
Celeste Simon, PhD*
M. Celeste Simon, Ph.D. is the Scientific Director of the Abramson Family Cancer Research Institute of the Perelman School of Medicine at the University of Pennsylvania. She received her bachelor's degree from Miami University and completed a Ph.D. in biochemistry at Rockefeller University in 1985. She conducted postdoctoral research with Joseph Nevins at Rockefeller and then Stuart Orkin at Harvard Medical School. Dr. Simon became an Assistant Professor of Medicine/Molecular Genetics and Cell Biology at the University of Chicago in 1992. In its first National Competition, she was named an Assistant Investigator of the Howard Hughes Medical Institute in 1994, remaining an HHMI investigator for twenty years, until August, 2014. In 1999, Dr. Simon moved to the University of Pennsylvania School of Medicine and was one of the founding laboratories of the newly formed Abramson Family Cancer Research Institute (AFCRI) there. She was promoted to Associate Professor of Cell and Developmental biology in 1999, and full Professor in 2006. In 2007, she became the Scientific Director of the AFCRI. Dr.
Simon's research is focused on how cells sense and respond to changes in the availability of molecular oxygen and nutrients. This affects normal development, physiology, and numerous diseases, such as the growth of solid tumors. The Simon Laboratory is studying how O2 sensing impacts tumor angiogenesis, inflammation, metabolism, metastasis, and overall disease progression. She is studying both animal models and cancer patient samples with the ultimate goal of developing novel strategies to treat tumors such as pancreatic cancer, soft tissue sarcoma, and colorectal cancer. Dr. Simon currently directs a laboratory of 20 individuals, including graduate students, postdoctoral fellows, clinical fellows, and research technicians. The AFCRI employs 400 researchers working in roughly 30 independent laboratories. Dr. Simon has received numerous awards recognizing her research, such as the Fouad Bashour Award for Distinguished Physiologists, Stanley N. Cohen Award for Biomedical Research, and Elliot Osserman Award from the Israel Cancer Research Fund. In 2014, she was elected to the American Academy of Arts and Sciences, as well as the Board of Directors for the American Association for Cancer Research.
University of Pennsylvania  
   
Loss of Mitochondrial Pyruvate carrier activity depletes Glutathione and impairs Hepatocellular Tumorigenesis
 Carver College of Medicine- U of Iowa Eric Taylor, PhD
 
Mitochondria are the engine of eukaryotic cellular metabolism. Mitochondria sustain cells with a continuous supply of ATP, replenish metabolic intermediates, and coordinate metabolic flux with numerous aspects of cellular biology. Accordingly, mitochondrial dysfunction is a root cause of devastating diseases, including cancer, neurodegeneration, and diabetes. The Taylor Lab is interested in the molecular mechanisms regulating mitochondrial function and their relationship to disease. Our research program is multidisciplinary, utilizing genetic, biochemical, cellular, and physiological experimental approaches. We have additional interest in problems related to skeletal muscle function and diabetes. Our current research projects focus on novel proteins important for mitochondrial function.
   
Plenary: Targeting ROS metabolism in cancer therapy
David Tuveson, MD, PhD*
 
Dr. Tuveson obtained a bachelor’s degree in chemistry at M.I.T. and medical and doctoral degrees at The Johns Hopkins University. He was a medical resident at Brigham and Women’s Hospital and a medical oncology fellow at Dana-Farber/Partners Cancer Care. During his postdoctoral years in Boston, Dr. Tuveson co-developed KIT inhibitors for gastrointestinal stromal tumors with George Demetri, and created several Kras- dependent mouse cancer models with Tyler Jacks. His lab also generated the first mouse models of ductal pancreatic cancer at the University of Pennsylvania. Subsequently he moved to the University of Cambridge, UK, to develop preclinical and clinical therapeutic strategies for pancreatic cancer. In Cambridge, his lab identified a variety of parameters that limit therapeutic efficacy in pancreatic cancer, including poor drug delivery and survival factors in the microenvironment. These findings are currently being evaluated in the clinic. In 2012, Dr. Tuveson was recruited back to the US to direct the Cancer Therapeutics Initiative within CSHL’s Cancer Center. He continues to practice medical oncology with an adjunct appointment at Memorial Sloan-Kettering Cancer Center and a clinical affiliation at Northwell Health. Dr. Tuveson serves on the Scientific Advisory Council for Stand up to Cancer and the SAB of the Georg Speyer Haus. Dr. Tuveson’s honors include the Rita Allen Foundation Scholar Award, the Waldenstrom Award (2014), the Hamdan Award (2016), and election to the American Society of Clinical Investigation (2016). Tuveson is the Roy J. Zuckerberg Professor of Cancer Research at CSHL, the head of the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, and is also the Lustgarten Foundation’s Director of Research.
Dr. Tuveson’s research and clinical focus is pancreatic cancer, a lethal malignancy that continues to lack effective clinical solutions. His research at CSHL is making progress toward finding a cure by detecting the disease earlier and designing novel therapeutic approaches, based in part on pancreatic organoid technology that he has pioneered and participates on many national and international committees and organizations to bring scientific findings into clinical evaluation for pancreatic cancer patients. His laboratory established a methodology for drug development in our mouse pancreatic cancer models, and thereby identified several therapeutic opportunities regarding stromal targeting that are now undergoing clinical evaluation. Furthermore, his group discovered several fundamental aspects of tumor progression including redox regulation and the role of genes in metastasis; developed human organoid models of pancreatic cancer, and using these organoids they have explored the basic biology of pancreatic cancer and investigated new therapeutic strategies.
Cold Spring Harbor Laboratory  
   
Plenary: Targeting cancer stem cell metabolism for improving therapy responses
Max Wicha, MD*
 
Dr. Wicha received his M.D. degree from Stanford University School of Medicine in 1974, trained in Internal medicine at the University of Chicago and in Medical Oncology at the NIH. His scientific career has focused on the biology and treatment of breast cancer. He has been a major leader in the science of cancer stem cells. His group was part of the team that first identified breast cancer stem cells, the first such cells identified in solid tumors. His laboratory has identified a number of cancer stem cell markers and developed in vitro and mouse models to isolate and characterize these cells, models which have been widely utilized in the field. His group has subsequently elucidated a number of intrinsic and extrinsic pathways which regulate stem cell self-renewal and cell fate decisions. This work has directly led to development of several clinical trials aimed at targeting breast cancer stem cells. Dr. Wicha is also the founding director of the University of Michigan Comprehensive Cancer Center, a position he held for 27 years. Under his leadership, the UMCCC established itself as one of the nation’s premier cancer centers. In 2015, Dr. Wicha stepped down as the Cancer Center Director enabling him to devote his full efforts to cancer stem cell research. He now holds the Madeline and Sidney Forbes Professor of Oncology Chair, and serves as Director of the Forbes Institute for Cancer Discovery. He was also recently appointed by President Obama to the National Cancer Advisory Board (NCAB). This board advises the NCI Director and Secretary of Health on matters related to cancer research and health policy.
University of Michigan
Comprehensive Cancer Center
 
   
One carbon unit metabolism, chromatin remodeling and cancer cell differentiation
Jiangbin Ye, PhD
Dr. Jiangbin Ye received his Ph.D in the Cancer Biology Program at University of Pennsylvania on 2010. His research in Dr. Constantinous Koumenis’ lab uncovered the critical role of GCN2-ATF4 pathway in sensing amino acid depletion and maintaining metabolic homeostasis in tumor cells (EMBO J. 2010).
During his graduate studies, Dr. Ye developed a strong interest in how cancer cells respond to nutrient signals and how metabolic alterations impact tumor progression. Intrigued by the emerging theory that cancer is a metabolic disease, he started the postdoctoral training in Dr. Craig Thompson’s lab at Memorial Sloan Kettering Cancer Center. Dr. discovered the unique role of serine and one-carbon unit metabolism in cancer cell proliferation, mitochondrial redox regulation, and survival upon oxidative stress (PNAS 2012, Nature 2014&Cancer Discovery 2014). His recent work also defined an important link between two major amino acid sensing mechanisms that regulate adaptation to fluctuating amino acid levels in the environment: Sestrin2 is a critical effector of GCN2 signaling that regulates amino acid homeostasis through mTORC1 suppression (Genes & Dev. 2015).
Dr. Ye initiated his independent research career at Stanford University, Department of Radiation Oncology as an Assistant Professor on 2016. His current research interests include: 1. The link between metabolic reprograming and epigenetic regulations in cancer. 2. How to target altered metabolic pathways in metastatic cancer. 3. The metabolic control of mTORC1 activity.

Stanford University  
 


RADIATION RESEARCH SOCIETY
380 Ice Center Lane, Suite C | Bozeman, MT 59718 | 1.877.216.1919
Member & Exhibitor Services: Audrey Rinehart |
1.877.216.1919  |  audrey@radres.org